Who Exports Escitalopram from India — 231 Suppliers Behind a $196.7M Market
India's escitalopram export market is supplied by 231 active exporters who collectively shipped $196.7M across 5,457 shipments. MEDISPRAY LABORATORIES PRIVATE LIMITED leads with a 39.4% market share, followed by AUROBINDO PHARMA LTD and TORRENT PHARMACEUTICALS LTD. The top 5 suppliers together control 71.5% of total export value, reflecting a concentrated market structure.
Top Escitalopram Exporters from India — Ranked by Export Value
MEDISPRAY LABORATORIES PRIVATE LIMITED is the leading escitalopram exporter from India, holding a 39.4% share of the $196.7M market across 5,457 shipments from 231 exporters. The top 5 suppliers — MEDISPRAY LABORATORIES PRIVATE LIMITED, AUROBINDO PHARMA LTD, TORRENT PHARMACEUTICALS LTD, SANDOZ PRIVATE LIMITED, AUROBINDO PHARMA LIMITED — collectively control 71.5% of total export value, indicating a highly concentrated market. Individual shares are: MEDISPRAY LABORATORIES PRIVATE LIMITED (39.4%), AUROBINDO PHARMA LTD (11.5%), TORRENT PHARMACEUTICALS LTD (8.4%), SANDOZ PRIVATE LIMITED (6.6%), AUROBINDO PHARMA LIMITED (5.6%).
Top Escitalopram Exporters from India
Ranked by export value · 231 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | MEDISPRAY LABORATORIES PRIVATE LIMITED S-CITAP 10 TABLETSS - CITAP 10 TABLETS - CITAP 20 TABLET | $77.6M | 1 | 39.4% |
| 2 | AUROBINDO PHARMA LTD ESCITALOPRAM TABLETS USP 20MGESCITALOPRAM TABLETS USP 10 MGESCITALOPRAM TABLETS USP 10MG 500'S | $22.5M | 21 | 11.5% |
| 3 | TORRENT PHARMACEUTICALS LTD ESCITALOPRAM TABLETS USP 20MGESCITALOPRAM TABLETS USP 10 MGESCITALOPRAM TABLETS USP 10MG 500'S | $16.6M | 14 | 8.4% |
| 4 | SANDOZ PRIVATE LIMITED ESCITALOPRAM OXA FCT 10MG IN91 SH EU 04MATERIAL NO. - 42030715, ESCITALOPRAM OXMATERIAL NO. - 42034110 ESCITALOPRAM OXA | $12.9M | 9 | 6.6% |
| 5 | AUROBINDO PHARMA LIMITED ESCITALOPRAM TABLETS USP 20MGESCITALOPRAM TABLETS USP 10 MGESCITALOPRAM TABLETS USP 10MG 500'S | $11.1M | 11 | 5.6% |
| 6 | SUN PHARMACEUTICAL INDUSTRIES LIMITED S-CITAP 10 TABLETSS - CITAP 10 TABLETS - CITAP 20 TABLET | $10.7M | 11 | 5.5% |
| 7 | CIPLA LIMITED S-CITAP 10 TABLETSS - CITAP 10 TABLETS - CITAP 20 TABLET | $7.9M | 7 | 4.0% |
| 8 | GRAVITI PHARMACEUTICALS PRIVATE LIMITED ESCITALOPRAM TABLETS USP 20MGESCITALOPRAM TABLETS USP 10 MGESCITALOPRAM TABLETS USP 10MG 500'S | $5.4M | 1 | 2.7% |
| 9 | TORRENT PHARMACEUTICALS LIMITED ESCITALOPRAM TABLETS USP 20MGESCITALOPRAM TABLETS USP 10 MGESCITALOPRAM TABLETS USP 10MG 500'S | $5.4M | 11 | 2.7% |
| 10 | IPCA LABORATORIES LIMITED ESCITALOPRAM SANDOZ 20 MG TESCITALOPRAM SANDOZ 10 MG TAPO-ESCITALOPRAM 10MG TABLETSESCITALOPR | $4.1M | 7 | 2.1% |
| 11 | INTAS PHARMACEUTICALS LIMITED ESCITALOPRAM OXA FCT 10MG IN91 SH EU 04MATERIAL NO. - 42034110 ESCITALOPRAM OXAESCITALOPRAM OXA FCT 10MG IN91 SH EU 06MATERIAL NO 42039084 | $4.1M | 10 | 2.1% |
| 12 | MICRO LABS LIMITED ESCITALOPRAM CRIS PHAR TABLETS 20MG [195ESCITALOPRAM OXALATE TABLETS 10MG ( SEROESCITALOPRAM OXALATE TABLETS 20MG ( ESCI | $3.0M | 10 | 1.5% |
| 13 | APOTEX RESEARCH PRIVATE LIMITED ESCITALOPRAM TABLETS USP 10MG (AURO-ESCIAPO-ESCITALOPRAM FCT 10MG 100 BTL 51667/APO-ESCITALOPRAM FCT 20MG 100 BTL 51668/ | $2.4M | 1 | 1.2% |
| 14 | MACLEODS PHARMACEUTICALS LTD ESCITALOPRAM TABLETS USP 20MGESCITALOPRAM TABLETS USP 10 MGESCITALOPRAM TABLETS USP 10MG 500'S | $2.2M | 13 | 1.1% |
| 15 | EMCURE PHARMACEUTICALS LIMITED ESCITALOPRAM TABLETS USP 10MG (AURO-ESCIAPO-ESCITALOPRAM FCT 10MG 100 BTL 51667/APO-ESCITALOPRAM FCT 20MG 100 BTL 51668/ | $2.1M | 1 | 1.1% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Escitalopram exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | Warning Letter, October 2 | Unknown | Unknown | Not verified | FDA issued a warning letter citing CGMP violations at the Indrad facility. |
| Aurobindo Pharma Limited | Warning Letter, June 2019 | Unknown | Unknown | Not verified | FDA issued a warning letter for CGMP deviations at the Pydibhimavaram facility. |
| Emcure Pharmaceuticals Limited | Warning Letter, August 20 | Unknown | Unknown | Not verified | FDA issued a warning letter for CGMP violations at the Hinjawadi facility. |
| Intas Pharmaceuticals Limited | Approved | Yes, April 2007 | Yes | Not verified | Intas received EU GMP certification in April 2007 for its biosimilar manufacturi |
| Sandoz Private Limited | Approved | Yes | Yes | Not verified | Sandoz facilities are approved by FDA, WHO, and EU authorities. |
| Sun Pharmaceutical Industries Limited | Approved | Yes | Yes | Not verified | Sun Pharma's manufacturing facilities have approvals from FDA, WHO, and EU autho |
| Cipla Limited | Approved | Yes | Yes | Not verified | Cipla's facilities are approved by FDA, WHO, and EU authorities. |
| MacLeods Pharmaceuticals Ltd | Approved | Yes | Yes | Not verified | MacLeods' manufacturing facilities have approvals from FDA, WHO, and EU authorit |
TransData Nexus reviewed the regulatory standing of 8 leading Escitalopram exporters from India. 5 hold US FDA facility approvals, 5 maintain WHO-GMP certification, and 5 are EU GMP compliant. 3 suppliers have received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Escitalopram sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a major hub for the production of Active Pharmaceutical Ingredients (APIs). The city hosts over 800 pharmaceutical companies, including prominent firms like Aurobindo Pharma Ltd., which contributed $22.5 million (11.5%) to Escitalopram exports between 2022 and 2026. The presence of Genome Valley, India's first biotech cluster, further enhances Hyderabad's capabilities in API manufacturing.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. This region contributes nearly 28% of India's pharmaceutical production and is home to companies like Torrent Pharmaceuticals Ltd., which accounted for $16.6 million (8.4%) of Escitalopram exports during the same period. The well-established infrastructure and regulatory compliance in this area make it a key player in the formulations sector.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a critical export gateway for Indian pharmaceuticals. This region's proximity to major ports facilitates efficient international distribution. Companies like Sun Pharmaceutical Industries Limited, headquartered in Mumbai, contributed $10.7 million (5.5%) to Escitalopram exports between 2022 and 2026. The area's robust logistics and export infrastructure support its role as a major export hub.
4Baddi-Nalagarh — Tax Incentive Zone
Located in Himachal Pradesh, the Baddi-Nalagarh region is Asia's largest pharmaceutical hub by volume. The area houses over 1,000 pharmaceutical manufacturing units, including Cipla Limited, which exported $7.9 million (4.0%) worth of Escitalopram during the specified period. Baddi's prominence is bolstered by favorable government policies, world-class infrastructure, and proximity to key markets.
5Sourcing Recommendations
- Diversify Supplier Base: To mitigate risks associated with supplier concentration, consider engaging with multiple suppliers across different clusters.
- Evaluate Supplier Capabilities: Assess the manufacturing capabilities and regulatory compliance of potential suppliers, especially those in Hyderabad and Ahmedabad-Vadodara, to ensure consistent quality and supply.
- Leverage Export Infrastructure: Utilize the export facilities in the Mumbai-Thane-Raigad region to streamline international distribution and reduce lead times.
- Consider Cost Advantages: Explore partnerships with manufacturers in the Baddi-Nalagarh region to benefit from tax incentives and cost-effective production.
By strategically sourcing from these diverse pharmaceutical clusters, companies can enhance supply chain resilience and optimize the procurement of Escitalopram.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Escitalopram exporters from India
Aurobindo Pharma Limited — Aurobindo partners with global pharma for respiratory product development
Aurobindo Pharma USA entered into a collaboration and license agreement with an unnamed global pharmaceutical company for the development and commercialization of specific products in the respiratory therapeutic category. The agreement spans an initial development period of three to five years, with both parties sharing development costs equally, capped at $90 million for Aurobindo. - IMPACT: This collaboration is not expected to directly impact Aurobindo's Escitalopram exports, as it focuses on the respiratory segment.
Impact: This collaboration is not expected to directly impact Aurobindo's Escitalopram exports, as it focuses on the respiratory segment.
Aurobindo Pharma Limited — Aurobindo acquires remaining stake in GLS Pharma to bolster oncology business
Aurobindo Pharma finalized the acquisition of the remaining 49% stake in GLS Pharma, a Hyderabad-based oncology company, achieving full ownership. This move enhances Aurobindo's capabilities in oncology APIs and formulations, including injectables and oral cancer therapies. - IMPACT: The acquisition is unlikely to affect Aurobindo's Escitalopram exports, as it primarily strengthens the company's oncology portfolio.
Impact: The acquisition is unlikely to affect Aurobindo's Escitalopram exports, as it primarily strengthens the company's oncology portfolio.
Torrent Pharmaceuticals Limited — Torrent Pharma acquires controlling stake in J.B. Chemicals from KKR
Torrent Pharmaceuticals agreed to acquire a controlling stake in J.B. Chemicals & Pharmaceuticals from KKR, purchasing a 46.39% stake with the potential to increase to 49.19%, followed by a mandatory open offer and a planned merger. - IMPACT: This acquisition may diversify Torrent's product portfolio, potentially influencing its Escitalopram export strategy.
Impact: This acquisition may diversify Torrent's product portfolio, potentially influencing its Escitalopram export strategy.
Common Questions — Escitalopram Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which escitalopram supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, MEDISPRAY LABORATORIES PRIVATE LIMITED leads with 77 recorded shipments worth $77.6M. AUROBINDO PHARMA LTD (605 shipments) and TORRENT PHARMACEUTICALS LTD (242 shipments) are also established high-volume exporters.
Q How many escitalopram manufacturers are there in India?
India has 231 active escitalopram exporters with a combined export market of $196.7M across 5,457 shipments to 95 countries. The top 5 suppliers hold 71.5% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for escitalopram from India?
Average FOB unit price: $2.25 per unit, ranging from $0.00 to $805.19. Average shipment value: $36.1K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 231 verified Indian exporters of Escitalopram ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 5,457 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 95 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
5,457 Verified Shipments
231 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists